The consistent evidence, obtained using multiple experimental approaches, that activation of MEK/ERK contributes to the inefficacy/persistence of JAK2 inhibitor treatment in pre-clinical MPN studies is both interesting and disappointing from a therapeutic standpoint. This evidence concerns the gene MAP2K7 and myeloproliferative neoplasm.